Figure 2 The efficacy of anti‐tumour necrosis factor (TNF) in the active drug group (Active) and the placebo group as the percentages of patients with an ACR20 response compared with the overestimation of the ACR20 response in eligible and ineligible daily clinical practice patients. AD, adalimumab; ET, etanercept; IN, infliximab.